INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

MLYSMineralys Therapeutics, Inc.

CIK 0001933414

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 20
Max Insider Score41
Connections12with evidence

MLYS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
CL
Coats LonnelDirector
MLYSMineralys Therapeutics, Inc.
Grant or award
A—
12.4K sh
Oct 19, 2026Oct 20, 2026
traded Oct 19, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Coats LonnelDirector · Oct 20, 2026
  • ← Insider ofevidence
    Peterson KristineDirector · Oct 20, 2026
  • ← Insider ofevidence
    Ferguson James J. IIIChief Medical Officer · Aug 12, 2026
9
CL
Coats LonnelDirector
MLYSMineralys Therapeutics, Inc.
Grant or award
A
—
16.6K sh
Oct 19, 2026
Oct 20, 2026
traded Oct 19, 2026
+1d
SEC FORM 4

Evidence

9
PK
Peterson KristineDirector
MLYSMineralys Therapeutics, Inc.
Grant or award
A—
12.4K sh
Oct 19, 2026Oct 20, 2026
traded Oct 19, 2026
+1dSEC FORM 4

Evidence

9
PK
Peterson KristineDirector
MLYSMineralys Therapeutics, Inc.
Grant or award
A—
16.6K sh
Oct 19, 2026Oct 20, 2026
traded Oct 19, 2026
+1dSEC FORM 4

Evidence

31
ST
Slingsby Brian TaylorDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$3.01M
104.3K sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

2
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$98K
7,438 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

0
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,438 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

13
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$209K
7,438 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

0
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
7,437 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

2
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$98K
7,437 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

13
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$193K
7,437 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

9
FJ
Ferguson James J. IIIChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Grant or award
A—
135.0K sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

9
FJ
Ferguson James J. IIIChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Grant or award
A—
102.4K sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,170 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,170 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

6
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
2,170 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

41
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2.70M
104.1K sh
Jun 26, 2026Jun 30, 2026
traded Jun 26, 2026
+4dSEC FORM 4

Evidence

20
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1.38M
104.1K sh
Jun 26, 2026Jun 30, 2026
traded Jun 26, 2026
+4dSEC FORM 4

Evidence

11
WE
Warren EricChief Commercial Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
104.1K sh
Jun 26, 2026Jun 30, 2026
traded Jun 26, 2026
+4dSEC FORM 4

Evidence

26
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.50M
58.0K sh
Jun 30, 2026Jun 30, 2026
traded Jun 30, 2026
+0dSEC FORM 4

Evidence

19
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$456K
17.0K sh
Jun 30, 2026Jun 30, 2026
traded Jun 30, 2026
+0dSEC FORM 4

Evidence

27
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
3,000 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
417 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

15
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$235K
9,890 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,438
417 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

20
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$115K
4,584 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

0
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,000 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

3
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,000 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,423
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

3
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$13K
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

10
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$176K
6,348 sh
Apr 15, 2026Apr 15, 2026
traded Apr 15, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,857
6,349 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

4
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,349 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

9
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$422K
15.7K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

13
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$373K
14.1K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

6
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,856
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

3
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$7,038
253 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

1
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
3,079 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

8
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$278K
10.7K sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

8
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$174K
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

4
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$66K
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

← Insider ofevidence
Warren Eric
Chief Commercial Officer · Jun 30, 2026
  • ← Insider ofevidence
    Rodman David MalcomChief Medical Officer · Jan 13, 2026
  • ← Insider ofevidence
    Catalys Pacific Fund, LP10% Owner · Nov 21, 2025
  • ← Insider ofevidence
    Slingsby Brian TaylorDirector, 10% Owner · Nov 21, 2025
  • ← Insider ofevidence
    Levy Adam ScottCFO and Secretary · Nov 13, 2025
  • ← Insider ofevidence
    Congleton JonDirector, Chief Executive Officer · Nov 13, 2025
  • ← Insider ofevidence
    Karydas DaphneDirector · Nov 13, 2025
  • ← Insider ofevidence
    Gold Alexander MDirector · Nov 13, 2025